Fludarabine Phosphate

如果说恶性肿瘤的标准治疗失败之后有什么办法，其实靶向药是针对肿瘤驱动基因突变来的，有些小类型的恶性肿瘤就是不存在驱动基因突变，这种情况是没有靶向药的治疗机会的，只能尝试免疫治疗，而免疫治疗则不局限是PD-1抑制剂，肿瘤浸润淋巴细胞药物（TIL）是一个很大的希望。 一、 GT101注射液治疗实体瘤患者（TIL） TIL疗法是一种从癌症患者自身病灶中，找到“抗癌突破口”的T细胞免疫疗法，又被喻为“实体瘤利器”。自1988年尝试用于临床以来，已历经数十年的发展历程，其在治疗转移性黑色素瘤、非小细胞肺癌（NSCLC）、晚期宫颈癌、结直肠癌（CRC）、卵巢癌、头颈部肿瘤中，展现出积极的临床效果。 GT101是沙砾生物自主研发的一款自体肿瘤浸润淋巴细胞（TIL）疗法，2022年4月22日，其临床试验默示许可获国家药品监督管理局（NMPA）批准（受理号：CXSL2200061），用于治疗非小细胞肺癌、黑色素瘤、宫颈癌等多款实体瘤。值得一提的是，GT101是我国首个获批临床的TIL细胞药物！有望成为首个攻克实体瘤的细胞药物！ 图片来源：网络 近日，在2024年美国临床肿瘤学年会ASCO大会上，公布了GT101 TIL疗法的1期临床试验（NCT05430373）结果。14例复发或转移性实体瘤（包括小细胞肺癌、黑色素瘤、宫颈癌）患者入组，这些患者的ECOG评分为0或1，先前接受过中位数为2.6线的既往治疗方案。首先，这些患者通过合适的手术方案，获取患者的肿瘤组织用于GT101的制备；之后进行TIL细胞的培养，制备过程约30天左右；最后，患者依次接受非清髓性淋巴细胞清除方案（环磷酰胺+氟达拉滨）、GT101回输治疗、IL-2（白细胞介素-2）治疗。 结果是相当让人振奋的，全部入组患者的客观缓解率（ORR）为35.7%。其中，28.6%（4例）患者达到部分缓解（PR）、57.1%（8例）达到病情稳定（SD）、7.1%（1例）患者幸运地获得了完全缓解（CR）。在宫颈癌患者（n=11）中：客观缓解率（ORR）达到45.5%，疾病控制率（DCR）高达90.9%（10/11）。 图片来自网络 目前这款药物正在招募临床标准治疗失败的实体瘤患者，希望大家积极报名申请，一旦入组之后药物和检查都是免费的。 二、入选标准 1、自愿加入研究，签署知情同意书，愿意而且能够遵守研究方案； 2、年龄18～55周岁（以签署知情同意当日计算）； 3、经组织学或细胞学确诊的不可根治性切除的复发或转移性的实体瘤； 4、经标准治疗失败、无标准治疗或经研究者判定不适合接受标准治疗； 5、至少有一个可切除的肿瘤病灶，用于制备自体肿瘤浸润淋巴细胞； 6、取样后，还应至少有一个符合RECIST 1.1标准定义的可测量病灶； 7、预期生存时间≥12周； 8、重要器官的功能符合下列要求（手术前14天内不允许使用任何血液成分及细胞生长因子治疗） 如您满足上面的情况，可以点击下面的临床试验小程序报名，招募专员会第一时间联系您。

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning Chemotherapy Opened for Enrollment FT522 Multi-indication IND Application for Conditioning-free Treatment of B Cell-mediated Autoimmune Diseases Allowed by FDA; Initial Phase 1 Clinical Data in B-cell Lymphoma to be Presented at ACR Convergence Initial Low-Dose Cohort of FT825 / ONO-8250 Shows Favorable Safety Profile in Phase 1 Solid Tumor Study; Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State $331 Million in Cash, Cash Equivalents and Investments with Projected Operating Runway through YE26 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the third quarter ended September 30, 2024. “We look forward to sharing initial Phase 1 clinical data of our off-the-shelf FT819 CAR T-cell product candidate in systemic lupus erythematosus at ACR Convergence and ASH. We continue to make great strides in our pursuit of therapeutic differentiation for patients with B cell-mediated autoimmune diseases, and patient enrollment is ongoing assessing FT819 with fludarabine-free conditioning as well as in a new treatment arm as add-on to maintenance therapy without conditioning chemotherapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “In addition, we are very pleased with the Phase 1 study design allowed by the FDA for our FT522 ADR-armed CAR NK cell product candidate in autoimmunity, which is designed to assess multiple doses of FT522 without conditioning chemotherapy across a basket of B cell-mediated autoimmune diseases, and we look forward to presenting an initial look at the clinical and translational data of FT522 in B-cell lymphoma at ACR.” FT819 iPSC-derived 1XX CAR T-cell Program Three Patients Treated in Phase 1 Autoimmunity Study using Fludarabine-free Conditioning. The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe systemic lupus erythematosus (SLE) is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819, the Company’s off-the-shelf CD8αβ+ T-cell product candidate that incorporates a CD19-targeted chimeric antigen receptor (CAR) with a novel 1XX costimulatory domain into the T-cell receptor alpha constant (TRAC) locus (NCT06308978). The first three patients, all of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either bendamustine alone or cyclophosphamide alone, followed by a single dose of FT819 at 360 million cells (Regimen A). All three patients remain on-study, and there have been no dose-limiting toxicities (DLTs) and no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD). The Company plans to present clinical and translational data from the first three patients at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA on December 7-10.First SLE Patient Case Study to be Presented at ACR Convergence. The first patient treated in the ongoing FT819 Phase 1 Autoimmunity study was a 27 year-old woman diagnosed with LN over ten years ago who received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. The first patient has completed six-month follow-up and remains on-study. The Company plans to present clinical and translational data from the first patient at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C. on November 16-19.Initiated Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning. The Company amended the clinical protocol of its FT819 Phase 1 Autoimmunity study to include a second treatment arm (Regimen B) to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The new arm is open for enrollment at a starting cell dose of 360 million cells, and is being conducted in parallel with Regimen A. FT825 / ONO-8250 iPSC-derived CAR T-cell Program Initial Phase 1 Clinical Data Presented at 2024 SITC. Under its collaboration with Ono Pharmaceutical Co., Ltd. (Ono), the Company is conducting a multi-center, Phase 1 study to assess the safety, pharmacokinetics, and activity of FT825 / ONO-8250, a multiplexed-engineered CAR T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2), in patients with advanced solid tumors (NCT06241456). At the 2024 Society of Immunotherapy of Cancer (SITC) 39th Annual Meeting, the Company presented initial clinical data from three heavily pre-treated patients, all of whom were previously treated with at least five prior lines of therapy including HER2-targeted therapy. Each patient was administered conditioning chemotherapy and a single dose of FT825 / ONO-8250 at the first dose level of 100 million cells. As of a data cutoff date of October 25, 2024, FT825 / ONO-8250 demonstrated a favorable safety profile with no DLTs and no events of any grade of CRS, ICANS, or GvHD. In addition, at Day 8 following treatment, peak CAR T-cell expansion was observed and phenotyping of FT825 / ONO-8250 sourced from the patients’ peripheral blood was indicative of an activated state (as evidenced by high levels of Granzyme B expression and maintenance of CAR expression) with no evidence of exhaustion (as evidenced by low levels of PD-1 and TIM3 expression). Enrollment is currently ongoing at the second dose level of 300 million cells as monotherapy and at the first dose level of 100 million cells in combination with epidermal growth factor receptor (EGFR)-targeted monoclonal antibody therapy.New Preclinical Data Demonstrates Cancer-selectivity of Novel H2CasMab-2 CAR. FT825 / ONO-8250 incorporates seven synthetic controls of cell function including a novel cancer-selective H2CasMab-2 CAR, which has exhibited similar potency with greater specificity for cancer cells expressing HER2 compared to trastuzumab in preclinical studies. New preclinical data presented at SITC demonstrated potent HER2-specific, anti-tumor activity in both in vitro and in vivo settings with limited cytolytic targeting of HER2+ normal cells. The on-tumor selectivity of FT825 / ONO-8250 was attributed to its incorporation of a novel HER2-targeted antigen binding domain, which was derived from a cancer-specific monoclonal antibody H2CasMab-2 (Kaneko et al., 2024), that was shown to differentially and preferentially recognize both locally misfolded HER2 and p95 truncation variants of HER2 as compared to trastuzumab. FT522 iPSC-derived CAR NK Cell Program Initial Clinical Data from Phase 1 BCL Study to be Presented at ACR Convergence. FT522 is the Company’s off-the-shelf, CD19-targeted CAR NK cell product candidate and its first to incorporate Alloimmune Defense Receptor (ADR) technology, which is designed to reduce or eliminate the need for administration of conditioning chemotherapy to patients receiving cell therapies. In its ongoing multi-center, Phase 1 clinical trial of FT522 in patients with relapsed / refractory B-cell lymphoma (BCL) (NCT05950334), the Company is currently enrolling patients in the second three-dose cohort at 900 million cells per dose with conditioning chemotherapy (Regimen A) and in the first three-dose cohort at 300 million cells per dose without conditioning chemotherapy (Regimen B). No DLTs, and no events of any grade of CRS, ICANS, or GvHD, have been reported in the Phase 1 study. The Company plans to present initial clinical and translational data from the Phase 1 BCL study at ACR Convergence.IND Application for Phase 1 Basket Study in Autoimmunity Allowed by FDA. The U.S. Food and Drug Administration (FDA) has allowed the Company’s Investigational New Drug (IND) application to assess the safety, pharmacokinetics, and activity of FT522 across a basket of B cell-mediated autoimmune diseases. The Phase 1 study is intended to treat patients with multiple doses of FT522 without conditioning chemotherapy as an add-on to rituximab induction therapy (Regimen A) and as an add-on to maintenance therapy in combination with rituximab (Regimen B). Dose escalation is expected to commence at 900 million cells per dose. The Company previously presented preclinical data from a novel re-challenge assay using peripheral blood mononuclear cells (PBMCs) from unmatched SLE donors, showing that FT522 uniquely drove rapid and deep CD19+ B cell depletion, maintained functional persistence, and eliminated alloreactive T cells, indicating that FT522 has the potential to function effectively in the presence of an unmatched host immune system. Third Quarter 2024 Financial Results Cash & Investment Position: Cash, cash equivalents, and investments as of September 30, 2024 were $330.5 million.Total Revenue: Revenue was $3.1 million for the third quarter of 2024, which was derived from the conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen under its collaboration with Ono.Total Operating Expenses: Total operating expenses were $55.5 million for the third quarter of 2024, including research and development expenses of $34.7 million and general and administrative expenses of $20.8 million. Such amounts included $11.8 million of non-cash stock-based compensation expense.Shares Outstanding: As of September 30, 2024, common shares outstanding were 113.9 million, pre-funded warrants outstanding were 3.9 million, and preferred shares outstanding were 2.8 million. Each preferred share is convertible into five common shares. About Fate Therapeutics’ iPSC Product PlatformHuman induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com. Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Company’s results of operations, financial condition, anticipated operating expenses and cash runway, and sufficiency of its cash and cash equivalents to fund its operations, as well as statements regarding the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress and timelines, and the objectives, plans and goals of its collaboration with Ono. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, the risk that the Company may not comply with its obligations under and otherwise maintain its collaboration agreement with Ono, the risk that research funding and milestone payments received by the Company under its collaboration may be less than expected, and the risk that the Company may incur operating expenses in amounts greater than anticipated. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share data)(unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Collaboration revenue$3,074 $1,944 $11,771 $61,857 Operating expenses: Research and development 34,650 34,275 101,392 140,780 General and administrative 20,801 18,948 58,907 63,513 Total operating expenses 55,451 53,223 160,299 204,293 Loss from operations$(52,377) $(51,279) $(148,528) $(142,436)Other income (expense): Interest income 4,438 4,697 13,414 12,772 Change in fair value of stock price appreciation milestones (13) 1,049 149 3,160 Other Income 274 363 856 9,698 Total other income, net 4,699 6,109 14,419 25,630 Net loss$(47,678) $(45,170) $(134, 109) $(116,806)Other comprehensive income: Unrealized gain on available-for-sale securities, net 1,257 88 820 1,355 Comprehensive loss$(46,421) $(45,082) $(133,289) $(115,451)Net loss per common share, basic and diluted$(0.40) $(0.46) $(1.19) $(1.19)Weighted–average common shares used to compute basic and diluted net loss per share 117,768,161 98,568,012 112,305,430 98,342,898 Condensed Consolidated Balance Sheets(in thousands)(unaudited) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents$37,909 $41,870 Accounts receivable 4,127 1,826 Short-term investments 259,014 273,305 Prepaid expenses and other current assets 9,244 14,539 Total current assets$310,294 $331,540 Long-term investments 33,607 980 Operating lease right-of-use asset 58,441 61,675 Other long-term assets 92,628 112,022 Total assets$494,970 $506,217 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses$29,929 $32,233 Deferred revenue 600 685 Operating lease liability, current portion 6,893 6,176 Total current liabilities$37,422 $39,094 CIRM award liability 1,940 --- Operating lease liability, net of current portion 92,085 97,360 Stock price appreciation milestones 1,197 1,346 Stockholders’ equity 362,326 368,417 Total liabilities and stockholders’ equity$494,970 $506,217 Contact:Christina TartagliaPrecision AQ212.362.1200christina.tartaglia@precisionaq.com